Abiopharma

SciSparc Notification (SPRC)

SciSparc Notification (SPRC)

New Form 8-K - U S PHYSICAL THERAPY INC /NV Filed: 2025-08-07 AccNo: 0000885978-25-000041 Size: 1 MB Item 2.02: Results of Operations and Financial Condition Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

New Form 8-K - COLLEGIUM PHARMACEUTICAL, INC Filed: 2025-08-07 AccNo: 0001558370-25-010647 Size: 4 MB Item 2.02: Results of Operations and Financial Condition Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

New Form 8-K - NORTECH SYSTEMS INC Filed: 2025-08-07 AccNo: 0001641172-25-022510 Size: 580 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

New Form 10-Q - PRECISION BIOSCIENCES INC Filed: 2025-08-07 AccNo: 0001628280-25-038594 Size: 6 MB

SciSparc-Clearmind Collaboration Leads to Publication of International Patent Application for Novel Combination Therapy Targeting Obesity and High Blood Sugar

Clearmind Medicine Announces Publication of International Patent Application for Novel Combination Therapy Targeting Obesity and High Blood Sugar

New Form 10-Q - NORTECH SYSTEMS INC Filed: 2025-08-07 AccNo: 0001641172-25-022507 Size: 5 MB

New Form 10-Q - REGENXBIO Inc. Filed: 2025-08-07 AccNo: 0001193125-25-174953 Size: 15 MB

New Form 10-Q - SAB Biotherapeutics, Inc. Filed: 2025-08-07 AccNo: 0000950170-25-104566 Size: 13 MB

Silence Therapeutics - Silence Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Intellia Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Company Progress

Cybin - Cybin Receives European Approval for EMBRACE, a Multinational Phase 3 Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

New Form 8-K - PRECISION BIOSCIENCES INC Filed: 2025-08-07 AccNo: 0001628280-25-038592 Size: 237 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits